Aldeyra Therapeutics (ALDX) Total Debt (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Total Debt came in at $15.3 million in Q1 2026, up 1.33% YoY from $15.1 million in Q1 2025, and down 49.42% on a QoQ basis from $30.2 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Total Debt (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Total Debt data on file, last reported at $15.3 million in Q1 2026.
- Quarterly Total Debt rose 1.33% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (up 1.33% YoY) and the FY2025 annual result came in at $30.2 million, up 101.24% from the prior year.
- Total Debt declined to $15.3 million in Q1 2026, from $30.2 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $30.2 million in Q4 2025 to a low of $15.0 million in Q1 2022.
- A 5-year average of $18.1 million and a median of $15.3 million in 2026 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2023 — Total Debt tumbled 41.28% — and 2025, when it surged 101.24%.
- Tracing ALDX's Total Debt over 5 years: stood at $15.8 million in 2022, then declined by 4.35% to $15.1 million in 2023, then dropped by 0.76% to $15.0 million in 2024, then surged by 101.24% to $30.2 million in 2025, then plunged by 49.42% to $15.3 million in 2026.
- The last three Total Debt figures came in at $15.3 million (Q1 2026), $30.2 million (Q4 2025), and $30.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.30 Mn |
| Dec 31, 2025 | 30.25 Mn |
| Sep 30, 2025 | 30.20 Mn |
| Jun 30, 2025 | 15.15 Mn |
| Mar 31, 2025 | 15.10 Mn |
| Dec 31, 2024 | 15.03 Mn |
| Sep 30, 2024 | 15.28 Mn |
| Jun 30, 2024 | 15.24 Mn |
| Mar 31, 2024 | 15.20 Mn |
| Dec 31, 2023 | 15.15 Mn |
| Sep 30, 2023 | 16.12 Mn |
| Jun 30, 2023 | 16.02 Mn |
| Mar 31, 2023 | 15.95 Mn |
| Dec 31, 2022 | 15.83 Mn |
| Sep 30, 2022 | 27.45 Mn |
| Jun 30, 2022 | 19.93 Mn |
| Mar 31, 2022 | 15.00 Mn |
| Dec 31, 2021 | 15.00 Mn |
| Sep 30, 2021 | 15.42 Mn |
| Jun 30, 2021 | 15.34 Mn |